Ensysce Biosciences (ENSC) Competitors $3.12 -0.08 (-2.50%) Closing price 03/27/2025 03:59 PM EasternExtended Trading$3.18 +0.06 (+1.92%) As of 03/27/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENSC vs. CYTH, LIAN, CMMB, NAII, LSTA, NNVC, BIVI, EGRX, LSB, and LPCNShould you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Cyclo Therapeutics (CYTH), LianBio (LIAN), Chemomab Therapeutics (CMMB), Natural Alternatives International (NAII), Lisata Therapeutics (LSTA), NanoViricides (NNVC), BioVie (BIVI), Eagle Pharmaceuticals (EGRX), Lakeshore Biopharma (LSB), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Ensysce Biosciences vs. Cyclo Therapeutics LianBio Chemomab Therapeutics Natural Alternatives International Lisata Therapeutics NanoViricides BioVie Eagle Pharmaceuticals Lakeshore Biopharma Lipocine Cyclo Therapeutics (NASDAQ:CYTH) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Do analysts recommend CYTH or ENSC? Cyclo Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 31.83%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cyclo Therapeutics is more favorable than Ensysce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Ensysce Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in CYTH or ENSC? Cyclo Therapeutics received 7 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 71.43% of users gave Cyclo Therapeutics an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote. CompanyUnderperformOutperformCyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Ensysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Which has more volatility and risk, CYTH or ENSC? Cyclo Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Is CYTH or ENSC more profitable? Ensysce Biosciences has a net margin of -179.26% compared to Cyclo Therapeutics' net margin of -2,847.19%. Cyclo Therapeutics' return on equity of 0.00% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cyclo Therapeutics-2,847.19% N/A -307.16% Ensysce Biosciences -179.26%-292.81%-158.83% Does the media prefer CYTH or ENSC? In the previous week, Cyclo Therapeutics had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for Cyclo Therapeutics and 2 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.44 beat Cyclo Therapeutics' score of 0.72 indicating that Ensysce Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Cyclo Therapeutics Positive Ensysce Biosciences Positive Do insiders and institutionals have more ownership in CYTH or ENSC? 68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings & valuation, CYTH or ENSC? Ensysce Biosciences has higher revenue and earnings than Cyclo Therapeutics. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclo Therapeutics$870.73K27.24-$20.06M-$0.90-0.80Ensysce Biosciences$2.23M1.97-$10.61M-$13.39-0.23 SummaryCyclo Therapeutics beats Ensysce Biosciences on 11 of the 18 factors compared between the two stocks. Remove Ads Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENSC vs. The Competition Export to ExcelMetricEnsysce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.38M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.117.2023.1319.03Price / Sales1.97226.00383.8993.17Price / CashN/A65.6738.1634.64Price / Book-1.016.476.944.33Net Income-$10.61M$141.90M$3.20B$247.06M7 Day Performance-12.36%-3.05%-2.32%-0.53%1 Month Performance-40.57%-4.63%3.07%-3.74%1 Year Performance-74.32%-8.61%11.16%1.72% Ensysce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENSCEnsysce Biosciences1.122 of 5 stars$3.12-2.5%N/A-74.3%$4.38M$2.23M-0.1110Short Interest ↓CYTHCyclo Therapeutics2.8933 of 5 stars$0.66-5.6%$0.95+43.7%N/A$21.76M$870,725.00-0.739Upcoming EarningsShort Interest ↓LIANLianBioN/A$0.20flatN/A-38.0%$21.61MN/A-0.25110Gap DownCMMBChemomab Therapeutics3.6877 of 5 stars$1.50+6.4%$9.00+500.0%+42.9%$21.54MN/A-1.5020Short Interest ↓News CoverageGap UpNAIINatural Alternatives International0.7867 of 5 stars$3.47-0.9%N/A-43.3%$21.51M$121.85M-2.69290Analyst ForecastShort Interest ↑News CoverageLSTALisata Therapeutics3.0647 of 5 stars$2.38-0.4%$15.00+530.3%-27.7%$20.52M$1M-0.9530Short Interest ↓Gap DownNNVCNanoViricidesN/A$1.31+6.5%N/A+7.1%$20.49MN/A-1.8220BIVIBioVie2.8889 of 5 stars$1.10+1.9%$3.00+172.7%+102.4%$20.30MN/A-0.1110Short Interest ↓News CoverageEGRXEagle PharmaceuticalsN/A$1.50+15.4%N/A-81.1%$19.48M$257.55M0.00100LSBLakeshore Biopharma1.5349 of 5 stars$2.05+2.3%N/AN/A$19.03M$672.27M0.00773Positive NewsGap DownLPCNLipocine2.1241 of 5 stars$3.50+4.5%$10.00+185.7%-36.5%$18.72M$7.92M-4.6110 Remove Ads Related Companies and Tools Related Companies CYTH Alternatives LIAN Alternatives CMMB Alternatives NAII Alternatives LSTA Alternatives NNVC Alternatives BIVI Alternatives EGRX Alternatives LSB Alternatives LPCN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENSC) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENSC Stock Free ENSC Stock Alerts